Skip to main content
OpenTrials
Completed

NCT Number: NCT01119898

Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis

Osteoarthritis (OA) is the most common form of arthritis. It can cause pain, swelling, and reduced motion in the joints. That can reduce quality of life.

OA can occur in any joint, but usually affects the hands, knees, hips or spine.

The purpose of this study is to find out if doctors might be able to use 2% PENNSAID gel to treat OA in the knee.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Osteoarthritis of the Knee Arthritis Joint Diseases Musculoskeletal Diseases Osteoarthritis Osteoarthritis, Knee Rheumatic Diseases

Age range

40 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Genova Clinical Research, Tucson, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Primary osteoarthritis of the knee
  • Radiologic evidence of OA of the knee
  • On stable pain therapy with an oral or topical NSAID or acetaminophen
  • Experience a "moderate flare" of pain following washout of stable pain therapy
  • Able to read and understand English or Spanish to answer pain assessment questions without any explanation
  • If female, surgically sterile or non-pregnant
  • Except for OA, in reasonably good general health
  • Written informed consent

Exclusion criteria

  • Secondary OA of the study knee
  • History of pseudo gout or inflammatory flare-ups
  • Participation would conflict with contraindications, warnings or precautions as stated in the prescribing information for oral or topical diclofenac
  • Severe, uncontrolled cardiac, renal, hepatic, or other systemic disease
  • Any malignancy within the previous 3 years, except local therapy for superficial skin cancer not on the study knee
  • Known sensitivity to the use of oral or topical diclofenac, aspirin [acetylsalicylic acid (ASA)] or any other NSAID, dimethyl sulfoxide (DMSO), or ethanol
  • Ongoing abnormality that could confound interpretation of the safety results (eg, anemia, unresponsive gastrointestinal [GI] reflux, etc.)
  • Documented gastroduodenal ulcer or any GI bleeding (except hemorrhoidal) within the last 6 months
  • Uncontrolled diabetes
  • Screening laboratory test results of serum creatinine ≥ 1.5 times upper limit of normal; aspartate aminotransferase (AST), alanine aminotransferase (ALT), or gamma-glutamyltransferase (GGT) ≥ 3 times upper limit of normal; and hemoglobin less than or equal to lower limit of normal
  • Documented alcohol or drug abuse within 1 year
  • If female, breast-feeding
  • Major surgery or previous damage to the study knee at any time, or minor knee surgery to the study knee within 1 year
  • Requires oral or intra-muscular corticosteroids, or received an intra articular corticosteroid injection into the study knee within the past 90 days, or into any other joint within the past 30 days, or currently applying topical corticosteroids onto the study knee
  • Received intra-articular viscosupplementation (eg, hylan G-F 20 [Synvisc®]) in the study knee in the past 6 months
  • On prior stable therapy (ie, more than 3 days per week for the previous month) with an opioid analgesic prior to the screening visit will be excluded.
  • Recently started taking a sedative hypnotic medication for insomnia
  • Taking anti-depressants
  • Not willing to discontinue prohibited medications/therapies
  • Cannot tolerate acetaminophen
  • Re-entering study after dropping out or withdrawn from study
  • Used another investigational drug within the previous 30 days
  • On or currently applying for disability benefits on the basis of knee OA
  • History of fibromyalgia
  • Other painful or disabling conditions affecting the knee or leg, or disabling condition of the hands (used to apply the study drug)
  • Skin disorder with current involvement on the hands (used to apply the study drug) or the knee(s) (application site)
  • Referred to an orthopedic surgeon for consideration of, or been advised to have, knee replacement or knee reconstruction surgery
  • Radiologic evidence of OA of the knee advanced to the point that all cartilage has been eroded (ie, bone on bone)
  • Recently started using a cane within the past 30 days
  • History of chronic headaches that may require more than occasional use of rescue medication for headaches

Treatment and study plan

PENNSAID Gel

Drug

2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks

Other names: diclofenac sodium 2.0% w/w

Vehicle

Drug

2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks

Primary outcomes

  1. Pain When Walking On A Flat Surface

    Time frame: at Baseline

    Participants rate their pain intensity when walking on a flat surface as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.

  2. Pain When Walking On A Flat Surface

    Time frame: at Week 4

    Participants rate their pain intensity when walking on a flat surface as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.

  3. Pain When Going Up Or Down Stairs

    Time frame: at Baseline

    Participants rate their pain intensity when going up or down stairs as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.

  4. Pain When Going Up Or Down Stairs

    Time frame: at Week 4

    Participants rate their pain intensity when going up or down stairs as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.

  5. Pain At Night While In Bed

    Time frame: at Baseline

    Participants rate their pain intensity at night while in bed as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.

  6. Pain At Night While In Bed

    Time frame: at Week 4

    Participants rate their pain intensity at night while in bed as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.

  7. Pain While Sitting Or Lying Down

    Time frame: at Baseline

    Participants rate their pain intensity while sitting or lying down as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.

  8. Pain While Sitting Or Lying Down

    Time frame: at Week 4

    Participants rate their pain intensity while sitting or lying down as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.

  9. Pain While Standing

    Time frame: at Baseline

    Participants rate their pain intensity while standing as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.

  10. Pain While Standing

    Time frame: at Week 4

    Participants rate their pain intensity while standing as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.

Sponsors and collaborators

Lead sponsor

Mallinckrodt

Industry

Registry information

Official study title

A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Clinical Study to Evaluate the Safety and Efficacy of PENNSAID Gel in the Symptomatic Treatment of Osteoarthritis of the Knee

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
May 10, 2010
Registry last updated
Oct 22, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.